rb 101 has been researched along with 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide in 1 studies
| Studies (rb 101) | Trials (rb 101) | Recent Studies (post-2010) (rb 101) | Studies (4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide) | Trials (4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide) | Recent Studies (post-2010) (4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide) |
|---|---|---|---|---|---|
| 57 | 0 | 2 | 279 | 0 | 85 |
| Protein | Taxonomy | rb 101 (IC50) | 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0842 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0879 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 4.7722 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 3.601 | |
| Mu-type opioid receptor | Homo sapiens (human) | 1.8083 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0086 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 3.85 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 2.48 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 6.066 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Folk, JE; Jutkiewicz, EM; Mosberg, HI; Rice, KC; Sobczyk-Kojiro, K; Torregrossa, MM; Watson, SJ; Woods, JH | 1 |
1 other study(ies) available for rb 101 and 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide
| Article | Year |
|---|---|
Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic Factor; Disulfides; Dose-Response Relationship, Drug; Electroencephalography; Enzyme Inhibitors; Frontal Lobe; Hippocampus; Injections, Intravenous; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Neprilysin; Phenylalanine; Piperazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Swimming | 2006 |